Amylyx Pharmaceuticals Financial Statements (AMLX)
|
|
|
|
Report date
|
|
|
31.12.2019 |
31.12.2020 |
31.03.2022 |
13.03.2023 |
22.02.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1.43 |
0.650 |
0.285 |
22.2 |
380.8 |
|
198.5 |
|
Operating Income, bln rub |
|
|
-13.6 |
-39.0 |
-82.7 |
-201.3 |
38.8 |
|
-249.3 |
|
EBITDA, bln rub |
? |
|
1.11 |
-39.0 |
-82.6 |
-200.9 |
39.9 |
|
-212.0 |
|
Net profit, bln rub |
? |
|
-14.8 |
-44.8 |
-87.9 |
-198.4 |
49.3 |
|
-259.5 |
|
|
OCF, bln rub |
? |
|
-10.7 |
-36.7 |
-74.8 |
-179.9 |
11.9 |
|
-95.1 |
|
CAPEX, bln rub |
? |
|
0.000 |
0.151 |
0.353 |
2.53 |
1.24 |
|
0.531 |
|
FCF, bln rub |
? |
|
-10.7 |
-36.8 |
-75.2 |
-182.4 |
10.7 |
|
-95.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
|
|
|
0.00% |
0.00% |
|
|
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
13.6 |
39.0 |
82.7 |
220.6 |
316.5 |
|
311.3 |
|
Cost of production, bln rub |
|
|
11.9 |
24.6 |
0.052 |
2.99 |
25.4 |
|
134.5 |
|
R&D, bln rub |
|
|
11.9 |
24.6 |
44.0 |
93.5 |
128.2 |
|
125.6 |
|
Interest expenses, bln rub |
|
|
1.28 |
2.29 |
0.000 |
4.29 |
0.000 |
|
3.46 |
|
|
Assets, bln rub |
|
|
3.22 |
14.1 |
105.6 |
391.5 |
517.5 |
|
250.7 |
|
Net Assets, bln rub |
? |
|
-25.4 |
-66.7 |
-151.2 |
340.6 |
433.4 |
|
196.2 |
|
Debt, bln rub |
|
|
14.9 |
1.43 |
0.000 |
6.28 |
4.24 |
|
2.57 |
|
Cash, bln rub |
|
|
3.09 |
12.9 |
96.1 |
346.9 |
371.4 |
|
234.4 |
|
Net debt, bln rub |
|
|
11.8 |
-11.5 |
-96.1 |
-340.7 |
-367.1 |
|
-231.8 |
|
|
Ordinary share price, rub |
|
|
|
|
|
37.0 |
14.7 |
|
|
|
Number of ordinary shares, mln |
|
|
56.5 |
56.5 |
57.9 |
66.5 |
67.2 |
|
68.1 |
|
|
Market cap, bln rub |
|
|
0 |
0 |
0 |
2 458 |
990 |
|
0 |
|
EV, bln rub |
? |
|
12 |
-11 |
-96 |
2 117 |
623 |
|
-232 |
|
Book value, bln rub |
|
|
-25 |
-67 |
-151 |
341 |
433 |
|
196 |
|
|
EPS, rub |
? |
|
-0.26 |
-0.79 |
-1.52 |
-2.98 |
0.73 |
|
-3.81 |
|
FCF/share, rub |
|
|
-0.19 |
-0.65 |
-1.30 |
-2.74 |
0.16 |
|
-1.40 |
|
BV/share, rub |
|
|
-0.45 |
-1.18 |
-2.61 |
5.12 |
6.45 |
|
2.88 |
|
|
EBITDA margin, % |
? |
|
78.1% |
-6 001% |
-28 995% |
-903.5% |
10.5% |
|
-106.8% |
|
Net margin, % |
? |
|
-1 039% |
-6 898% |
-30 835% |
-892.4% |
12.9% |
|
-130.7% |
|
FCF yield, % |
? |
|
|
|
|
-7.42% |
1.08% |
|
|
|
ROE, % |
? |
|
58.4% |
67.2% |
58.1% |
-58.2% |
11.4% |
|
-132.2% |
|
ROA, % |
? |
|
-460.1% |
-317.9% |
-83.2% |
-50.7% |
9.52% |
|
-103.5% |
|
|
P/E |
? |
|
0.00 |
0.00 |
0.00 |
-12.4 |
20.1 |
|
0 |
|
P/FCF |
|
|
0.00 |
0.00 |
0.00 |
-13.5 |
92.7 |
|
0 |
|
P/S |
? |
|
0.00 |
0.00 |
0.00 |
110.6 |
2.60 |
|
0 |
|
P/BV |
? |
|
0.00 |
0.00 |
0.00 |
7.22 |
2.28 |
|
0 |
|
EV/EBITDA |
? |
|
10.6 |
0.29 |
1.16 |
-10.5 |
15.6 |
|
1.09 |
|
Debt/EBITDA |
|
|
10.6 |
0.29 |
1.16 |
1.70 |
-9.20 |
|
1.09 |
|
|
R&D/CAPEX, % |
|
|
|
16 287% |
12 476% |
3 700% |
10 329% |
|
23 650% |
|
|
CAPEX/Revenue, % |
|
|
0.00% |
23.2% |
123.9% |
11.4% |
0.33% |
|
0.27% |
|
| Amylyx Pharmaceuticals shareholders |
